202 related articles for article (PubMed ID: 27513756)
21. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
Tolley K; Kemmett D; Thybo S; Nasr R; Smethurst H
Eur J Health Econ; 2016 Apr; 17(3):287-304. PubMed ID: 25795391
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results.
Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Goncalves J; Larsson T; Skov T; Swanson N
J Drugs Dermatol; 2014 Feb; 13(2):154-60. PubMed ID: 24509965
[TBL] [Abstract][Full Text] [Related]
23. PICATO (ingenol mebutate 0.015% and 0.05% gels): a novel treatment for actinic keratosis.
Abramovits W; Oquendo M; Vincent KD; Gupta AK
Skinmed; 2013; 11(2):111-5. PubMed ID: 23745230
[No Abstract] [Full Text] [Related]
24. Relapse of pemphigus vulgaris after topical application of ingenol mebutate.
Russo I; Ferrazzi A; Alaibac M
Clin Exp Dermatol; 2016 Aug; 41(6):664-6. PubMed ID: 27381839
[TBL] [Abstract][Full Text] [Related]
25. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
Keating GM
Drugs; 2012 Dec; 72(18):2397-405. PubMed ID: 23231025
[TBL] [Abstract][Full Text] [Related]
26. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes.
Augustin M; Tu JH; Knudsen KM; Erntoft S; Larsson T; Hanke CW
J Am Acad Dermatol; 2015 May; 72(5):816-21. PubMed ID: 25770879
[TBL] [Abstract][Full Text] [Related]
27. Local skin reactions following the administration of topical ingenol mebutate for actinic keratosis.
Conde-Taboada A; Mercado B; Aranegui B; González-Guerra E; López-Bran E
Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469731
[TBL] [Abstract][Full Text] [Related]
28. Management of local skin reactions after the application of ingenol mebutate gel for the treatment of actinic keratosis: four illustrative cases.
Longo C; Neri L; Argenziano G; Calvieri S; Calzavara-Pinton PG; Cantisani C; Catricalà C; Peris K; Peserico A; Pimpinelli N; Pellacani G
J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):320-1. PubMed ID: 25186255
[No Abstract] [Full Text] [Related]
29. A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body.
Pellacani G; Peris K; Guillen C; Clonier F; Larsson T; Venkata R; Puig S
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2192-8. PubMed ID: 26300464
[TBL] [Abstract][Full Text] [Related]
30. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.
Gupta AK; Paquet M
J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300
[TBL] [Abstract][Full Text] [Related]
31. Squamous cell carcinoma developed after ingenol mebutate therapy: a possible consequence of the treatment?
Maglie R; Grandi V; Maio V; Pileri A
G Ital Dermatol Venereol; 2018 Jun; 153(3):442-443. PubMed ID: 29766707
[No Abstract] [Full Text] [Related]
32. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
[TBL] [Abstract][Full Text] [Related]
33. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial.
Erlendsson AM; Karmisholt KE; Haak CS; Stender IM; Haedersdal M
J Am Acad Dermatol; 2016 Apr; 74(4):709-15. PubMed ID: 26810403
[TBL] [Abstract][Full Text] [Related]
34. Erosive pustular dermatosis of the scalp induced by ingenol mebutate.
Brambilla L; Tourlaki A; Nazzaro G
G Ital Dermatol Venereol; 2018 Oct; 153(5):743-745. PubMed ID: 28895376
[No Abstract] [Full Text] [Related]
35. Biological Effects of Ingenol Mebutate Gel in Moderate to Severe Actinic Fields Assessed by Reflectance Confocal Microscopy: A Phase I Study.
Ulrich M; Lange-Asschenfeldt S; Skak K; Skov T; Østerdal ML; Röwert-Huber HJ; Zibert JR; Stockfleth E
J Drugs Dermatol; 2016 Oct; 15(10):1181-1189. PubMed ID: 27741334
[TBL] [Abstract][Full Text] [Related]
36. Clinical Response to Ingenol Mebutate in Patients With Actinic Keratoses.
Batalla A; Flórez Á; Feal C; Peón G; Abalde MT; Salgado-Boquete L; de la Torre C
Actas Dermosifiliogr; 2015 Dec; 106(10):e55-61. PubMed ID: 26055975
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12-month study.
Garbe C; Basset-Seguin N; Poulin Y; Larsson T; Østerdal ML; Venkata R; Lear JT
Br J Dermatol; 2016 Mar; 174(3):505-13. PubMed ID: 26471889
[TBL] [Abstract][Full Text] [Related]
38. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis.
Jim On SC; Haddican M; Yaroshinsky A; Singer G; Lebwohl M
Cutis; 2015 Jan; 95(1):47-51. PubMed ID: 25671445
[TBL] [Abstract][Full Text] [Related]
39. Ingenol Mebutate: Expanded Utility.
Khalfe Y; Rosen T
J Drugs Dermatol; 2020 Feb 1 j; 19(2):156-161. PubMed ID: 32129959
[TBL] [Abstract][Full Text] [Related]
40. Granuloma faciale successfully treated with ingenol mebutate.
Bobyr I; Campanati A; Consales V; Giangiacomi M; Diotallevi F; Offidani A
Dermatol Ther; 2016 Sep; 29(5):325-329. PubMed ID: 27364361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
